HIV VACCINE RATIONALE

HIV 疫苗的基本原理

• 批准号: 7562280
• 负责人: JULIA L HURWITZ
• 金额: $ 7.16万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7562280
• 关键词: Animals; Antibodies; Antigens; B-Lymphocytes; Binding; Biological Assay; Cell physiology; Computer Retrieval of Information on Scientific Projects Database; Control Animal; DNA; Data; Funding; Grant; HIV; HIV-1; HIV-1 vaccine; Human; Immune response; Infection; Institution; Interferon Type II; Life; Measures; Proteins; Protocols documentation; Research; Research Personnel; Resources; Source; T-Lymphocyte; United States National Institutes of Health; Vaccinated; Vaccines; Vaccinia virus; Viral; antibody-dependent cell cytotoxicity; base; design; in vivo; killings; prevent; response; simian human immunodeficiency virus; success; vaccine efficacy

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A major obstacle to the design of a global HIV-1 vaccine is viral diversity. At present, data suggest that a vaccine comprising a single antigen will fail to generate broadly reactive B-cell and T-cell responses able to confer protection against the diverse isolates of HIV-1. We focus on an HIV-1 vaccine cocktail strategy, prompted by cocktail vaccine successes in other fields. The multi-vectored, multi-envelope vaccine strategy elicits HIV-1-specific B- and T-cell functions (measured by antibody binding, neutralization, antibody-dependent cell-mediated cytotoxicity and gamma interferon assays), with a diversity and durability that may be required to prevent HIV-1 infections in humans. Based on the success of previous vaccine studies at TNPRC, in this study we will compare the efficacy of 4 vaccine protocols to unvaccinated control animals. Animals were vaccinated with a combination of some or all of DNA, live and killed recombinant vaccinia virus expressing HIV-env, and HIV protein. Assays measuring cellular and humoral immune response indicate a strong, broadly based immune response to SHIV. Animals will be challenged with SHIV to assess vaccine efficacy in vivo.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 全球HIV-1疫苗设计设计的主要障碍是病毒多样性。目前，数据表明，包含单个抗原的疫苗将无法产生广泛反应性的B细胞和T细胞反应，能够赋予针对HIV-1不同分离株的保护。我们专注于HIV-1疫苗鸡尾酒策略，在其他领域的鸡尾酒疫苗成功促成。多矢量的多个螺旋疫苗策略引发了HIV-1特异性B和T细胞功能（通过抗体结合，中和，中和，抗体依赖性细胞介导的细胞毒性和γ干扰素测定法测量），具有预防HIV HIV-1感染所需的多样性和耐用性。 根据先前在TNPRC的疫苗研究的成功，在这项研究中，我们将比较4种疫苗方案对未接种疫苗的对照动物的功效。 用某些或全部DNA，活的和杀死表达HIV-ENV和HIV蛋白的重组离子病毒的重组牛ac病毒和杀死的重组牛ac病毒和杀死动物的疫苗接种。 测量细胞和体液免疫反应的测定表明对SHIV的强烈，基于广泛的免疫反应。 动物将受到SHIV的挑战，以评估体内疫苗功效。